KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Moderna (MRNA) Free Cash Flow (2018 - 2025)

Moderna (MRNA) has disclosed Free Cash Flow for 8 consecutive years, with $891.0 million as the latest value for Q4 2025.

  • On a quarterly basis, Free Cash Flow rose 10.55% to $891.0 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$2.1 billion, a 33.41% increase, with the full-year FY2025 number at -$2.1 billion, up 33.41% from a year prior.
  • Free Cash Flow was $891.0 million for Q4 2025 at Moderna, up from -$953.0 million in the prior quarter.
  • In the past five years, Free Cash Flow ranged from a high of $4.0 billion in Q2 2021 to a low of -$1.5 billion in Q2 2024.
  • A 5-year average of $462.7 million and a median of $106.0 million in 2022 define the central range for Free Cash Flow.
  • Peak YoY movement for Free Cash Flow: surged 9493.02% in 2021, then tumbled 959.51% in 2023.
  • Moderna's Free Cash Flow stood at $3.2 billion in 2021, then plummeted by 40.5% to $1.9 billion in 2022, then tumbled by 96.68% to $63.0 million in 2023, then surged by 1179.37% to $806.0 million in 2024, then increased by 10.55% to $891.0 million in 2025.
  • Per Business Quant, the three most recent readings for MRNA's Free Cash Flow are $891.0 million (Q4 2025), -$953.0 million (Q3 2025), and -$849.0 million (Q2 2025).